Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders
Donald R. StainesVolume:
66
Year:
2006
Language:
english
DOI:
10.1016/j.mehy.2005.08.006
File:
PDF, 38 KB
english, 2006